

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7245217

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JONATHAN ALEXANDER TERRETT	08/21/2019
DEMETRIOS KALAITZIDIS	08/26/2019
LAWRENCE KLEIN	08/19/2019
RECEIVING PARTY DATA	
Name:	CRISPR THERAPEUTICS AG
Street Address:	BAARERSTRASSE 14
City:	ZUG
State/Country:	SWITZERLAND
Postal Code:	6300
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16613057
CORRESPONDENCE DATA	
Fax Number:	(617)535-3800
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6175353981
Email:	cameyer@mwe.com, IPDocketBoston@mwe.com
Correspondent Name:	MCDERMOTT WILL & EMERY
Address Line 1:	200 CLARENDON STREET
Address Line 2:	58TH FLOOR
Address Line 4:	BOSTON, MASSACHUSETTS 02116-5021
ATTORNEY DOCKET NUMBER:	095136-0056
NAME OF SUBMITTER:	CASSANDRA MEYER
SIGNATURE:	/Cassandra Meyer/
DATE SIGNED:	03/25/2022
Total Attachments: 7	
source=CT98-PCT Fully-Executed Assignment document#page1.tif	
source=CT98-PCT Fully-Executed Assignment document#page2.tif	
source=CT98-PCT Fully-Executed Assignment document#page3.tif	

source=CT98-PCT Fully-Executed Assignment document#page4.tif
source=CT98-PCT Fully-Executed Assignment document#page5.tif
source=CT98-PCT Fully-Executed Assignment document#page6.tif
source=CT98-PCT Fully-Executed Assignment document#page7.tif

ASSIGNMENT BY INVENTORS

WE, the undersigned Assignor(s), Jonathan Alexander Terrett, Demetrios Kalaitzidis, and Lawrence Klein of Cambridge, Massachusetts, for good and valuable consideration paid to us by

CRISPR Therapeutics AG

a Corporation of Zug, Switzerland having its principal place of business at Baarerstrasse 14, 6300 Zug, Switzerland, the receipt and sufficiency of which is hereby acknowledged, do hereby sell, assign, transfer and set over unto said

CRISPR Therapeutics AG

its successors, legal representatives and assigns, the entire right, title and interest for the United States of America and all jurisdictions worldwide including all rights of priority under the Paris Convention for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the jurisdiction in which any such protection is sought in connection with subject matter including the invention or improvement in

MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY

described in an application, in any form or embodiment thereof

Executed by us of even date herewith and about to be filed

or

Application No. PCT/IB2018/001619, filed on May 11, 2018

This application claims the benefit of the following application(s):

- Application No. 62/505,649, filed on May 12, 2017
- Application No. 62/508,862, filed on May 19, 2017
- Application No. 62/538,138, filed on July 28, 2017
- Application No. 62/567,012, filed on October 2, 2017
- Application No. 62/567,008, filed on October 2, 2017
- Application No. 62/583,793, filed on November 9, 2017
- Application No. 62/639,332, filed on March 6, 2018
- Application No. 62/648,138, filed on March 26, 2018
- Application No. 62/655,510, filed on April 10, 2018.

in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all jurisdictions worldwide which may or shall be granted on or otherwise directed to said invention, or any equivalent or parts thereof or improvements now or hereafter made, or on said application, or any continuing, divisional, extension, provisional, reexamination, reissue, renewal, substitute, supplemental examination or other applications based in whole or in part thereon, and all rights to seek compensation for past infringement of said invention worldwide. And we agree, for ourselves and our executors and administrators, with said Corporation and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said Corporation, with specifications and claims in such form as shall be approved by the counsel of said Corporation and to vest and confirm in said Corporation, its successors and assigns, the legal title to all such patents.

And we do hereby authorize CRISPR Therapeutics AG to file, or forego filing, patent applications in any jurisdictions worldwide on said invention in the name of the Assignee.

And we do hereby authorize the Commissioner of Patents of the United States and any authority of any jurisdiction whose duty it is to issue protections on inventions as aforesaid, to issue such Letters Patent as shall be granted upon said application or applications based thereon to said Corporation, its successors, legal representatives and assigns, the same to be held by Assignee for its own use and benefit and the use and benefit of its successors, legal representatives and assigns to the full end of the term or terms for which Letters Patents may be granted and/or extended.

And we do hereby represent and covenant that, at the time of execution and delivery of this instrument, except for any rights, titles and interests that have arisen to Assignee under law or that have already been transferred to Assignee, we/[Assignor] is/are the sole and lawful owner of the entire right, title and interest in and to the said inventions above-mentioned, and that the same are unencumbered and that we/[Assignor] have/has good and full right and lawful authority to convey the same to Assignee in the manner herein set forth, and that we have executed, and will not execute, any instrument in conflict herewith.

And we do further hereby grant the attorneys/agents of Nelson Mullins Riley & Scarborough LLP, the power to insert on this Assignment the filing date and/or application number of said application or any further identification of the invention, or any assignor/assignee address or incorporation information which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

And we do further hereby agree that should any provision of this Assignment be determined to be void, invalid, unenforceable or against public policy, such provision may be altered in time or scope in order to give effect to such provision. If such alteration is not possible, such provision shall be deemed as severed from this Assignment and the remainder of this Assignment shall remain in full force and effect, so long as the original intent of this Assignment remains substantially intact.

CRISPR Reference:CT98-PCT
NM Reference: CRTN-098PC

This Assignment shall be interpreted and construed according to, and governed by, the laws of Zug, Switzerland.


In witness whereof, CRISPR Therapeutics AG and the inventors hereunto set this Assignment to be executed, and agree to be legally bound thereby, as of the dates indicated below.

Date: 8/21/19


Signed: 
JONATHAN ALEXANDER TERRETT

United States of America)
State of Massachusetts)
County of Middlesex)

On this 21st day of August, 2019 before me, the undersigned notary public, personally appeared JONATHAN ALEXANDER TERRETT, proved to me through satisfactory evidence of identification to be the person whose name is signed on the preceding or attached document in my presence.

 (Notary Signature and Seal)

My commission expires: 8/15/2025




Date: 8/26/19


Signed: 
DEMETRIOS KALAITZIDIS

United States of America)
State of Massachusetts)
County of Middlesex)

On this 26th day of August, 2019 before me, the undersigned notary public, personally appeared DEMETRIOS KALAITZIDIS, proved to me through satisfactory evidence of identification to be the person whose name is signed on the preceding or attached document in my presence.

 (Notary Signature and Seal)

My commission expires: 8/15/2025




Date: 8/19/2019


Signed: 
LAWRENCE KLEIN

United States of America _____)
State of Massachusetts _____)
County of Middlesex _____)

On this 19th day of August, 2019 before me, the undersigned notary public, personally appeared LAWRENCE KLEIN, proved to me through satisfactory evidence of identification to be the person whose name is signed on the preceding or attached document in my presence.

 (Notary Signature and Seal)

My commission expires: 8/15/2025



ASSIGNEE:

I hereby acknowledge that rights in the above-identified application(s) have transferred from the Assignor(s) by virtue of their above execution of this Assignment and are hereby conveyed to CRISPR Therapeutics AG, the Assignee, of which I am an authorized signatory.

Date: 29.8.2019

Signed: 
SIGNATORY SIGNATURE

ANDERS KASSING
SIGNATORY PRINTED NAME

EXECUTIVE DIRECTOR IP
SIGNATORY TITLE

CRISPR Therapeutics AG